Handelsavisen
prelaunch
Companies Healthcare KROS.NS
KR
KROS.NS NSE (India) Pharmaceuticals & Medical Research

Kros.Ns

$203,08
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
12,0 %
ROE
11,1 %
Net margin
7,7 %
Debt / equity
0,08
Beta
52w range
Volume
Day range
Prev close
$11,31
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

KROS.NS is an Indian company engaged in the manufacturing and supply of auto, truck, and motorcycle parts, primarily serving the automotive industry.

Business. Keros Therapeutics Inc (KROS.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY9 analysts
5 buy4 hold0 sell
Avg 12m price target22,17

Analyst recommendations

9 analysts · consensus Buy
Buy5
Hold4
Sell0
12-month price target
22,17
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
9 analysts · indicative
Ownership
Arrowstreet Capital, Limited Partnership
largest disclosed fund holder
Profitability
11,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning KROS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to KROS.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Keros Therapeutics Inc (KROS.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    KROS.NS maintains a strong liquidity position, with a current ratio of 3.21, indicating the company can easily cover its short-term liabilities with its current assets. The company also holds INR 804.34 million in cash and equivalents, which provides a buffer against short-term obligations. However, the operating cash flow is negative at INR -320.59 million, suggesting that the company's core operations are not currently generating positive cash flow. Free cash flow, on the other hand, is positive at INR 265.18 million, indicating that the company has sufficient cash flow to fund operations and potentially invest in growth after capital expenditures.

    In terms of profitability, KROS.NS reports a return on equity (ROE) of 11.05% and a return on assets (ROA) of 8.38%, both of which are strong indicators of efficient use of equity and assets to generate profits. The company's gross profit of INR 2.13 billion and operating income of INR 744.08 million further support its profitability. The debt-to-equity ratio of 0.08 suggests that the company is not heavily leveraged and has a conservative capital structure.

    KROS.NS operates in a single business segment focused on auto, truck, and motorcycle parts, with no disclosed geographic diversification. The company's revenue is concentrated in this segment, and there is no information provided on geographic revenue distribution. This concentration may expose the company to risks associated with the performance of the automotive industry and regional economic conditions.

    The company's growth trajectory is not explicitly outlined in the available data, but the positive free cash flow and strong ROE suggest potential for reinvestment and expansion. The capital expenditure of INR -283.56 million indicates that the company is investing in its operations, which could support future growth. However, the negative operating cash flow may limit the company's ability to fund growth initiatives without external financing.

    KROS.NS is currently assessed as having low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and substantial cash reserves reduce the likelihood of near-term dilution. However, the negative operating cash flow could become a concern if it persists, potentially leading to the need for additional financing and possible dilution.

    There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The company's financial statements do not indicate any major legal, regulatory, or operational issues that would affect its performance in the near term.

    Key takeaways
    • KROS.NS has a strong liquidity position with a current ratio of 3.21 and INR 804.34 million in cash and equivalents.
    • The company's ROE of 11.05% and ROA of 8.38% indicate efficient use of equity and assets to generate profits.
    • KROS.NS is not heavily leveraged, with a debt-to-equity ratio of 0.08, suggesting a conservative capital structure.
    • The company's free cash flow of INR 265.18 million supports potential reinvestment and expansion.
    • The negative operating cash flow of INR -320.59 million may limit the company's ability to fund growth without external financing.
    • The company is assessed as having low liquidity and dilution risk, with no immediate filing-based flags detected.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $203,08
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $4.35B
    Net cash
    $465.2M
    Current ratio
    3.2
    Debt / equity
    0.1
    ROA
    8.4%
    ROE
    11.1%
    Cash conversion
    -67.0%
    CapEx / revenue
    -4.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)KROS 1,6% · rank #9 of 109

    Business relationships

    Business relationships3 disclosed relationships · 2 types · extracted from filings & disclosures
    Partners1
    Subsidiaries2
    EX21:10041f82b276EX21:10041f82b276Subsidiarie97%
    EX21:25d3ff6b7666EX21:25d3ff6b7666Subsidiarie97%

    Supply chain

    Vendors → KROS ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSKROSKROSKros.Ns3 entitiesTakeda PharmaceuticPharmaceuticalsUS
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs KROS · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    +17,0 vs self
    Div yield
    vs self
    ROE
    40,4 %
    +11,7 vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    -76,5 vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    -188,9 vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    +53,0 vs self
    Div yield
    vs self
    ROE
    5,1 %
    -23,6 vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    +8,5 vs self
    Div yield
    vs self
    ROE
    18,9 %
    -9,8 vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    -86,2 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -5,34
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    9
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-22 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$16,00
    Mean$22,17
    Median$20,00
    High$30,00
    Spot$203,08
    −89.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin12,0 %Above P75
    Net Margin7,7 %Above P75
    ROE11,1 %Above P75
    Capex / Rev-4,6 %Below median
    D/E0,08Below median
    Cash Conv-0,67Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 591 453 sh1 exercises · 12 grants10 insiders
    • BIENAIME JEAN JACQUESDirector · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
    • Seth AlpnaDirector · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
    • GRAY MARY ANNDirector · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
    • Farzan NimaDirector · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
    • Knowles JuliusDirector · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
    • Seehra JasbirDirector, CHIEF EXECUTIVE OFFICER · Employee Stock Option (Right to Buy) → Common StockDisposed 55 000 @ $0,30exercise · 2026-04-02
    • Newton Charles W.Director · Stock Option (Right to Buy) → Common StockAcquired 14 788 @ $11,35grant · 2026-03-09
    • Regnante KeithCHIEF FINANCIAL OFFICER · Employee Stock Option (Right to Buy) → Common StockAcquired 60 000 @ $15,52grant · 2026-02-24
    • Seehra JasbirDirector, CHIEF EXECUTIVE OFFICER · Employee Stock Option (Right to Buy) → Common StockAcquired 217 000 @ $15,52grant · 2026-02-24
    • Seehra JasbirDirector, CHIEF EXECUTIVE OFFICER · Employee Stock Option (right to buy) → Common StockAcquired 100 000 @ $15,52grant · 2026-02-24
    • Cho EstherChief Legal Officer · Employee Stock Option (Right to Buy) → Common StockAcquired 80 000 @ $15,52grant · 2026-02-24
    • Lerner Lorena RaquelChief Scientific Officer · Employee Stock Option (Right to Buy) → Common StockAcquired 75 000 @ $15,52grant · 2026-02-24
    • Seehra JasbirDirector, CHIEF EXECUTIVE OFFICER · Employee Stock Option (right to buy) → Common StockAcquired 62 500 @ $63,61grant · 2026-01-07

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • KROS.NS Market data — financials · 2026-05-28

    Ownership & reference

    Top holders

    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,00 %$7M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$115M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$4M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$4M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$8M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$31M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$3M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$1M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$2M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$1M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$1M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$6M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,00 %$1M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling4 buys · 8 sellsnet -$367K10 insiders · last 365d
    • BIENAIME JEAN JACQUESDirector · Common StockBought 1 000 @ $10,19$10K · 2026-06-15
    • Newton Charles W.Director · Common StockSold 550 @ $10,04$6K · 2026-06-11
    • Knowles JuliusDirector · Common StockSold 2 625 @ $10,73$28K · 2026-06-04
    • Seth AlpnaDirector · Common StockSold 2 625 @ $10,72$28K · 2026-06-04
    • Farzan NimaDirector · Common StockSold 2 625 @ $10,73$28K · 2026-06-04
    • Seth AlpnaDirector · Common StockOther 7 142 · 2026-06-03
    • GRAY MARY ANNDirector · Common StockOther 7 142 · 2026-06-03
    • Farzan NimaDirector · Common StockOther 7 142 · 2026-06-03
    • BIENAIME JEAN JACQUESDirector · Common StockOther 7 142 · 2026-06-03
    • Knowles JuliusDirector · Common StockOther 7 142 · 2026-06-03
    • BIENAIME JEAN JACQUESDirector · Common StockBought 1 000 @ $10,58$11K · 2026-05-15
    • BIENAIME JEAN JACQUESDirector · Common StockBought 1 000 @ $11,70$12K · 2026-04-15
    • Seehra JasbirDirector, CHIEF EXECUTIVE OFFICER · Common StockOther 55 000 @ $0,30$16K · 2026-04-02
    • Newton Charles W.Director · Common StockOther 13 215 · 2026-03-09
    • BIENAIME JEAN JACQUESDirector · Common StockBought 2 000 @ $11,21$22K · 2026-03-09
    • Seehra JasbirDirector, CHIEF EXECUTIVE OFFICER · Common StockSold 7 015 @ $16,17$113K · 2026-02-19
    • Lerner Lorena RaquelChief Science Officer · Common StockSold 3 873 @ $16,35$63K · 2026-02-18
    • Cho EstherSVP, General Counsel · Common StockSold 4 745 @ $16,35$78K · 2026-02-18
    • Regnante KeithCHIEF FINANCIAL OFFICER · Common StockSold 4 739 @ $16,35$77K · 2026-02-18

    Short positioning

    1.1Mshares short+3.2% vs prior
    4.08days to cover
    36.0%short of daily vol
    296fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    KROS.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    KROSTAK.OEX21:100EX21:25dPharmaceutical
    This companySectorPartnersSubsidiaries

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -21.3%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -45.1%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -48.7%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.12xDerived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 146.0%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -19.7%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 146.8%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -47.0%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -25.3%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 166.8%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 146.4%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 132.0%Derived (calculated)
    • Net margin (FY 2025-12-31): 35.7%Derived (calculated)
    • Return on equity (FY 2025-12-31): 28.7%Derived (calculated)
    • Return on assets (FY 2025-12-31): 25.7%Derived (calculated)
    • Current ratio (FY 2025-12-31): 15.45xDerived (calculated)
    • Cash & equivalents (annual): USD 287.42MSEC XBRL filing
    • Revenue (annual): USD 243.86MSEC XBRL filing
    • Operating income (annual): USD 67.57MSEC XBRL filing
    • Capex (annual): USD 1.55MSEC XBRL filing
    • Total assets (annual): USD 338.02MSEC XBRL filing
    • Total liabilities (annual): USD 34.89MSEC XBRL filing
    • Pre-tax income (annual): USD 91.9MSEC XBRL filing
    • R&D expense (annual): USD 129.64MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-15 00:00 UTCINSIDER15 insider transactions — 2026-06 · $100k gross 5 derivative
    2026-06-15INSIDERBIENAIME JEAN JACQUES bought 1.0k sh — Director ~$10k
    2026-06-11INSIDERNewton Charles W. sold 550 sh — Director ~$6k
    2026-06-04INSIDERKnowles Julius sold 2.6k sh — Director ~$28k
    2026-06-04INSIDERSeth Alpna sold 2.6k sh — Director ~$28k
    2026-06-04INSIDERFarzan Nima sold 2.6k sh — Director ~$28k
    2026-06-03FILING8-K filing →
    2026-06-03INSIDERSeth Alpna transacted 7.1k sh — Director
    2026-06-03INSIDERGRAY MARY ANN transacted 7.1k sh — Director
    2026-06-03INSIDERFarzan Nima transacted 7.1k sh — Director
    2026-06-03INSIDERBIENAIME JEAN JACQUES transacted 7.1k sh — Director
    2026-06-03INSIDERKnowles Julius transacted 7.1k sh — Director
    2026-06-03INSIDERFarzan Nima acquired 7.4k sh Stock Option (right to buy) — Director
    2026-06-03INSIDERSeth Alpna acquired 7.4k sh Stock Option (right to buy) — Director
    2026-06-03INSIDERGRAY MARY ANN acquired 7.4k sh Stock Option (right to buy) — Director
    2026-06-03INSIDERBIENAIME JEAN JACQUES acquired 7.4k sh Stock Option (right to buy) — Director
    2026-06-03INSIDERKnowles Julius acquired 7.4k sh Stock Option (right to buy) — Director
    2026-06-01FILING8-K filing →
    2026-05-15 00:00 UTCINSIDER1 insider transaction — 2026-05
    2026-05-15INSIDERBIENAIME JEAN JACQUES bought 1.0k sh — Director ~$11k
    2026-05-14FILING10-Q filing →
    2026-05-14FILING8-K filing →
    2026-04-22FILINGDEF 14A filing →
    2026-04-15 00:00 UTCINSIDER3 insider transactions — 2026-04 1 derivative
    2026-04-15INSIDERBIENAIME JEAN JACQUES bought 1.0k sh — Director ~$12k
    2026-04-02INSIDERSeehra Jasbir transacted 55.0k sh — Director, CHIEF EXECUTIVE OFFICER ~$16k
    2026-04-02INSIDERSeehra Jasbir disposed of 55.0k sh Employee Stock Option (Right to Buy) — Director, CHIEF EXECUTIVE OFFICER
    2026-03-09 00:00 UTCINSIDER3 insider transactions — 2026-03 1 derivative
    2026-03-09FILING8-K filing →
    2026-03-09INSIDERNewton Charles W. transacted 13.2k sh — Director
    2026-03-09INSIDERBIENAIME JEAN JACQUES bought 2.0k sh — Director ~$22k
    2026-03-09INSIDERNewton Charles W. acquired 14.8k sh Stock Option (Right to Buy) — Director
    2026-03-04FILING8-K filing →
    2026-03-04FILING10-K filing →
    2026-03-04FILING8-K filing →
    2026-02-26FILING8-K filing →
    2026-02-24 00:00 UTCINSIDER9 insider transactions — 2026-02 · net sell $332k 5 derivative
    Showing the 40 most recent of 53 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage